Cookies on our website

We use cookies on our website. To learn more about cookies, how we use them on our site and how to change your cookie settings please view our cookie policy. By continuing to use this site without changing your settings you consent to our use of cookies in accordance with our cookie policy.

Read more Close
Skip Ribbon Commands
Skip to main content
Sign In

Publications

Generic consistency evaluation in China: the coming paradigm shift in drug pricing and patent cliff

 

18 April 2017

China is one of the largest generic drug markets in the world. As part of the drug approval reform, the ongoing generic consistency evaluation (GCE) is likely to have significant, long-lasting impacts on the market landscape, drug pricing and generic competition. Patent cliff might inevitably follow and should be examined and planned for early.

To read the full publication, please click here.

 

Publications search




Key people

David Shen
David Shen
Head of IP China - Shanghai
China and Hong Kong
Telephone icon+852 2974 6938
Send email
View officeView profile
Related expertise

Intellectual Property

Life Sciences

Related links

Importance of patents in Chinese pharmaceutical tendering

Client alerts

Already signed up for Client alerts? Click here to access your portal



  • Add comment (optional)